Episode Details

A major shift is happening in Washington — and this time, it directly involves federal healthcare.In this episode of TDR Cannabis in 5, presented by Flowhub, Shadd Dales breaks down the launch of a new Medicare-backed pilot program led by Dr. Mehmet Oz that will allow coverage for hemp-derived CBD products — with the potential to expand into THC-related products over time.This marks a significant moment for the cannabis industry.For the first time, the U.S. government is not just regulating cannabinoids — it’s stepping in as a payer, helping fund access for patients through Medicare. The program is expected to begin as early as April and could provide coverage of up to $500 per year for eligible patients, primarily seniors.But this isn’t just about access.It introduces a new framework built around compliance, safety, and medical oversight. Products will need to meet strict standards for testing, labeling, and consistency — something the broader hemp market has struggled with for years.At the same time, there are still key unknowns around supplier approvals, qualifying conditions, and how distribution will work in practice.For operators and investors, this represents a structural shift — moving cannabinoids closer to a healthcare-driven model rather than a traditional retail one.And with that shift comes opportunity — but also higher barriers to entry.#CannabisNews #CBD #Medicare #CannabisPolicy #Hemp #CannabisIndustry #CannabisInvesting #TDR #Healthcare #CannabisStocksWant to see more Cannabis Reform videos?🎬    • Five Positive Cannabis Trends in 2026 | TD...  🎬    • Cannabis Rescheduling Back in Focus After ...  🎬    • SAM Lawsuit Targets CBD Medicare Program |...  🎬    • White House Meetings Signal New CBD Rules ...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram: <